FDA orders J&J to cite death risks with taking Natrecor

04/26/2005 | NYTimes.com

Johnson & Johnson is changing the packaging insert for its heart failure drug, Natrecor, to state an increased risk of death associated with the medicine. The firm acted on orders from the FDA that notified Scios, J&J's subsidiary that makes the drug, that the information intended for professionals needed to be revised, citing at least seven published journal studies.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations